Perspectives on the development of imatinib and the future of cancer research.
Druker
Brian J
BJ
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA. drukerb@ohsu.edu
D001363:Awards and Prizes; D001549:Benzamides; D002986:Clinical Trials as Topic; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000266:history* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000266:history* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000266:history* / Q000627:therapeutic use*; D012106:Research / Q000639:trends*; D014481:United States
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate